Результаты поиска

The need for venous thromboembolism (VTE) prophylaxis in plastic surgery.

The reader is presumed to have a broad understanding of plastic surgical procedures and concepts. After studying this article, the participa … is. Other forms of chemoprophylaxis are coming onto the market or under development. In particular, fondaparinux, an indirect FXa inhibitor, was approved in 2004 for VTE prophylaxis in orthopedic surgery. Studies have indicated that it is significantly more effective than LMWH after joint replacement, hip fracture surgery, and in cancer patients. Other drugs i …

The influence of new antithrombotic drugs on regional anesthesia.

PURPOSE OF REVIEW: Antithrombotic drugs are known to increase the risk of spinal epidural hematoma after neuraxial blockade. During the last few years, several new anticoagulants have been introduced, some of them more potent than the drugs currently available. More potency, however, may also indicate a higher risk of bleeding. RECENT FINDINGS: Case series from the last few years indicate that spinal epidural hematoma is more common then previously estimated, with a prevalence from 1: 100,000 in obstetric patients to as high as 1: 3,600 in female orthopedic patients. In order to diminish this

The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.

Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the t

Совпадение в полном тексте источника
… Initially, 237 patients with DVT and 240 patients with PE were treated, respectively, with fondaparinux or enoxaparin and with fondaparinux or UFH. All patients went on to receive vitamin K antagonists. … FDA approved fondaparinux in the initial treatment of VTE [ 128 ]. …

Anticoagulation use is associated with lower fetal fraction and more indeterminate results.

BACKGROUND: Maternal anticoagulation use may increase indeterminate result rates on cell-free DNA-based screening, but existing studies are … d heparin-derived products (unfractionated heparin, low-molecular-weight heparin), clopidogrel, and fondaparinux, with a separate group for those on aspirin alone. An indeterminate result was defined as fetal fraction <4%. We evaluated the association between maternal anticoagulation or aspirin use, and fetal fraction, indeterminate results, and total cell-fre …

Management of Venous Thromboembolism for Patients With Hematologic Malignancies.

Advanced practitioners are an integral part of the cancer care team. Therefore, it is imperative they are knowledgeable of risk factors associated with venous thromboembolism in the oncology setting, including signs or symptoms and management.

Совпадение в полном тексте источника
… FACTOR Xa INHIBITORS Factor Xa inhibitors—apixaban (Eliquis), edoxaban (Savaysa), rivaroxaban (Xarelto), fondaparinux—have had limited use in oncology. … Label: fondaparinux sodium-fondaparinux sodium injection 2016 Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm? …

Venous thromboembolism in cancer patients: an underestimated major health problem.

Venous thromboembolism (VTE) is a major health problem among patients with cancer, its incidence in this particular population is widely increasing. Although VTE is associated with high rates of mortality and morbidity in cancer patients, its severity is still underestimated by many oncologists. Thromboprophylaxis of VTE now considered as a standard of care is still not prescribed in many institutions; the appropriate treatment of an established VTE is not yet well known by many physicians and nurses in the cancer field. Patients are also not well informed about VTE and its consequences. Many

Совпадение в полном тексте источника
… LMWH, fondaparinux, or UFH can equally be used [ 48 - 50 , 61 - 65 ]. There is a trend toward to prefer LMWH and fondaparinux over UFH because of their ease of administration. Once started, prophylaxis should be continued till full recovery or until discharge from hospital [ 48 - 50 , 65 ]. … As to fondaparinux, one randomized controlled trial compared fondaparinux and LMWH. In a post hoc analyses of cancer patients’ subgroup, rates of recurrence at 3 months and major bleeding were not different between the two groups [ 85 , 88 ]. …

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature.

Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. The management of special situations-including recurrent venous thromboembolism (VTE), thrombosis at unusual sites, and central venous catheter-associated thrombosis (CVC-AT)-remains particularly challenging because of the limited availability of high-quality evidence. This narrative review synthesizes recommendations from major international and Spanish clinical practice guidelines and expert consensus documents, including those from SEOM, ESMO, ASCO, NCCN, ITAC and SEMI, to provide a struc

Совпадение в полном тексте источника
… Patients receiving DOAC therapy: Switching to LMWH [ 1 , 3 , 4 , 6 , 10 ] fondaparinux, or UFH [ 4 ]. Patients receiving fondaparinux: Switching to LMWH, a DOAC, or UFH [ 4 ]. Patients receiving VKA: Switching to LMWH, a DOAC [ 1 , 3 , 4 , 6 , 10 ], fondaparinux, or UFH [ 4 ]. … Fondaparinux or UFH may be considered in selected cases when these agents are contraindicated. 3.2.5. …

Cancer-associated thrombosis: prevention and treatment.

Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent

Совпадение в полном тексте источника
… And although fondaparinux appears to be comparable to lmwh in efficacy and safety, limited data are available for it in the cancer setting, and a specific antidote for it is lacking. … A post hoc subgroup analysis of cancer patients in a randomized trial found a lower risk of vte with fondaparinux than with dalteparin, but that finding requires confirmation in future studies 12 . …

Clinical guide SEOM on venous thromboembolism in cancer patients.

Venous thromboembolism (VTE) is a common event in cancer patients and one of the major causes of cancer-associated mortality and a leading cause of morbidity. In recent years, the incidence rates of VTE have notably increased; however, VTE is still commonly underestimated by oncologists. VTE is considered an adverse prognostic factor in cancer patients in all settings. In 2011 the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of prophylaxis and treatment of VTE in cancer patients. In an effort to incorporate evidence obtained since the original publication, SE

Совпадение в полном тексте источника
… Finally, it has been suggested that fondaparinux is less efficacious than LMWH. … Alternative agents are UFH and fondaparinux according to the patient’s characteristics and clinical situation. …

[Comments on the 2010 guidelines on cardiopulmonary resuscitation of the European Resuscitation Council].

ADULTS: Administer chest compressions (minimum 100/min, minimum 5 cm depth) at a ratio of 30:2 with ventilation (tidal volume 500-600 ml, in … (60 mg p.o.). Antithrombins, such as heparin (60 IU/kgBW, max. 4000 IU), enoxaparin, bivalirudin or fondaparinux depending on the diagnosis (STEMI or non-STEMI-ACS) and the planned therapeutic strategy. In STEMI define reperfusion strategy depending on duration of symptoms until PCI, age and location of infarction. TRAUMA: In severe hemorrhagic shock, definiti …

Anticoagulation for people with cancer and central venous catheters.

BACKGROUND: Central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer. Thrombosis often necessitates th … unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), vitamin K antagonists (VKA), or fondaparinux with no intervention or placebo or comparing the effects of two different anticoagulants in people with cancer and a CVC. DATA COLLECTION AND ANALYSIS: Teams of two review authors independently used a standardized form to extract data in duplicate. …

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

BACKGROUND: Rivaroxaban has been shown to be efficacious for treatment of venous thromboembolism in adults, and has a reduced risk of bleedi … objectively confirmed venous thromboembolism previously treated with low-molecular weight heparin, fondaparinux, or a vitamin K antagonist for at least 2 months or, in children who had catheter-related venous thromboembolism for at least 6 weeks. We administered rivaroxaban orally in a bodyweight-adjusted 20 mg-equivalent dose, based on physiologically-based …

Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.

Cancer-associated venous thromboembolism (CA-VTE) is a significant complication in oncology, contributing to morbidity, mortality, and increased healthcare utilization. Due to multiple patient- and disease-related factors, patients with cancer are at a markedly elevated risk for VTE, particularly within the first 6 months of diagnosis. The aim of this review is to provide an overview of current challenges and unmet needs in CA-VTE prediction, prevention and management. While the Khorana score remains the most widely used risk stratification tool, its limited sensitivity has prompted the develo

Совпадение в полном тексте источника
… Unlike heparin and other LMWH, fondaparinux does not bind to platelet factor 4 (PF4), conferring negligible risk of heparin-induced thrombocytopenia (HIT) [ 130 ]. … Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs N. Engl. J. Med. 2010 363 1222 1232 10.1056/NEJMoa0912072 20860504 134. …

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1)

Совпадение в полном тексте источника
… Fondaparinux and unfractionated heparin remain acceptable alternative treatment options without new evidence. … Regarding patients with previous heparin-induced thrombocytopenia (definite or possible), the literature search did not retrieve any specific data in patients with cancer concerning the common practice on the use of fondaparinux. …

Cancer-Associated Thrombosis: A New Light on an Old Story.

Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There are additional risk factors for thrombosis specific to cancer including cancer type, histology, and treatment, such as chemotherapy. Recently developed scoring systems use these risk factors to stratify the degree of risk and encourage thromboprophylaxis in intermediate- to high-risk patients. Anticoagulation is safely used for prophylaxis and treatment of CAT. Both of these h

Совпадение в полном тексте источника
… Fondaparinux or VKA may also be used. … ISTH/ [ 114 , 115 ]/2019 | Recommend UFH, LMWH and fondaparinux for all patients with acute medical illness. LMWH is preferred over UFH due to lower major bleeding risk. Consider fondaparinux if previous history of HIT. DOACs are not recommended for prophylaxis. …

Venous thromboembolism in the cancer population: pathology, risk, and prevention.

Patients with cancer have an increased risk of developing venous thromboembolism (VTE) and the incidence of these events has been increasing over the past decade. Venous thromboembolic events include both deep venous thrombosis and pulmonary embolism. These events contribute to higher morbidity and mortality rates. Understanding the complex pathogenesis of and risk factors for cancer-associated VTE will help guide advanced practitioners to improve outcomes with prophylaxis. The American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the European Society of Medical

Совпадение в полном тексте источника
… Agents that may be used based on patient characteristics include low molecular weight heparins (LMWHs), unfractionated heparin (UFH), fondaparinux, aspirin, or warfarin. … All of the guidelines recommend the use of low-dose UFH, LMWH, or fondaparinux for prophylaxis without a particular preference (Khorana, 2007; Lyman et al., 2007; Mandala, Falanga, & Roila, 2009). …

Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.

Cancer-associated venous thromboembolism (VTE) is a frequent, potentially life-threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer-associated thrombosis (CAT); factor Xa-inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low-molecular-weight heparin for the treatment of CAT indicated that DOACs are

Совпадение в полном тексте источника
… in hospitalized patients confined to bed Surgery: LMWH, UFH, or fondaparinux | Inpatient: LMWH, fondaparinux, UFH, or warfarin b Surgery: LMWH, fondaparinux, UFH, or warfarin; perioperative dosing with UFH or LMWH for high‐risk surgery (eg, abdominal or pelvic) b | Inpatient: Pharmacological thromboprophylaxis … recommended in the absence of bleeding or other contraindications Perioperative: UFH or LMWH unless contraindicated because of active bleeding or high bleeding risk | Inpatient: LMWH or fondaparinux when CrCl ≥ 30 mL/min, or UFH in hospitalized patients with reduced mobility Surgery: LMWH (when CrCl …

Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. We address a) the appropriate workup to search for occult malignancy in patients with idiopathic VTE, b) identification of high-risk cancer patients for primary thromboprophylaxis, c) the appropriate immediate and long-term treatment for people with cancer diagnosed with acute t

Совпадение в полном тексте источника
… Dosing regimens for prevention and treatment of VTE in patients with malignancy (Adapted from ASCO [ 7 ]) Drug Regimen Pharmacologic (anticoagulant) prophylaxis a Hospitalized medical patients b Unfractionated heparin 5000 U once every 8 h c Dalteparin 5000 U once daily Enoxaparin 40 mg once daily Fondaparinux … once daily thereafter c Dalteparin | 2500 U 2–4 h preoperatively and 5000 U once daily thereafter or 5000 U 10–12 h preoperatively and 5000 U once daily thereafter Enoxaparin | 20 mg 2–4 h preoperatively and 40 mg once daily thereafter or 40 mg 10–12 h preoperatively and 40 mg once daily thereafter Fondaparinux …

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Complex does not bind thrombin due to short length DVT prophylaxis Acute DVT/PE Acute coronary syndrome HITT (no cross reactivity with heparin-dependent anti-platelet antibodies) For DVT prophylaxis, fondaparinux 2.5 mg SC daily (start 6–8 h after surgical hemostasis) For acute clots, fondaparinux 5 … Complex does not bind thrombin due to short length | DVT prophylaxis Acute DVT/PE Acute coronary syndrome HITT (no cross reactivity with heparin-dependent anti-platelet antibodies) | For DVT prophylaxis, fondaparinux 2.5 mg SC daily (start 6–8 h after surgical hemostasis) For acute clots, fondaparinux …

Cancer-associated thrombosis: an overview.

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Emerging data have enhanced our understanding of cancer-associated thrombosis, a major cause of morbidity and mortality in patients with cancer. In addition to VTE, arterial occlusion with stroke and anginal symptoms is relatively common among cancer patients, and is possibly related to genetic predisposition. Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, ch

Совпадение в полном тексте источника
… Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389–96. doi: 10.1111/j.1538-7836.2011.04487.x. 47. Nagler M, Haslauer M, Wuillemin WA. … Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129(4):407–17. doi: 10.1016/j.thromres.2011.10.037. 48. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. …